Evidence map›Paper›PMID 34307847›Full record

ArticleAACE clinical case reports

ICAM1-Negative Intravascular Large B-Cell Lymphoma of the Pituitary Gland: A Case Report and Literature Review.

Kumiko Naito, Sawako Suzuki, Chikako Ohwada, Kazuki Ishiwata, Yutaro Ruike, Akiko Ishida, Hanna Deguchi-Horiuchi, Masanori Fujimoto, Hisashi Koide, Emiko Sakaida and 7 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in AACE clinical case reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Kumiko NaitoDepartment of Endocrinology, Hematology and Gerontology, Chiba University Hospital, Chiba, Japan.
Sawako SuzukiDepartment of Endocrinology, Hematology and Gerontology, Chiba University Hospital, Chiba, Japan.
Chikako OhwadaDepartment of Endocrinology, Hematology and Gerontology, Chiba University Hospital, Chiba, Japan.
Kazuki IshiwataDepartment of Endocrinology, Hematology and Gerontology, Chiba University Hospital, Chiba, Japan.
Yutaro RuikeDepartment of Endocrinology, Hematology and Gerontology, Chiba University Hospital, Chiba, Japan.
Akiko IshidaDepartment of Endocrinology, Hematology and Gerontology, Chiba University Hospital, Chiba, Japan.
Hanna Deguchi-HoriuchiDepartment of Endocrinology, Hematology and Gerontology, Chiba University Hospital, Chiba, Japan.
Masanori FujimotoDepartment of Endocrinology, Hematology and Gerontology, Chiba University Hospital, Chiba, Japan.
Hisashi KoideDepartment of Endocrinology, Hematology and Gerontology, Chiba University Hospital, Chiba, Japan.
Emiko SakaidaDepartment of Endocrinology, Hematology and Gerontology, Chiba University Hospital, Chiba, Japan.
Kentaro HoriguchiDepartment of Neurological Surgery, Chiba University Hospital, Chiba, Japan.
Yasuo IwadateDepartment of Neurological Surgery, Chiba University Hospital, Chiba, Japan.
Ichiro TatsunoCenter for Diabetes, Metabolism and Endocrinology, Toho University Sakura Medical Center, Chiba, Japan.
Naoko InoshitaDepartment of Pathological Diagnosis, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.
Jun-Ichiro IkedaDepartment of Pathology, Chiba University Hospital, Chiba, Japan.
Tomoaki TanakaDepartment of Molecular Diagnosis, Chiba University, Chiba, Japan.
Koutaro YokoteDepartment of Endocrinology, Hematology and Gerontology, Chiba University Hospital, Chiba, Japan.
Chiba University Hospital · JPChiba University · JPToho University Medical Center Sakura Hospital · JPTokyo Metropolitan Geriatric Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIntravascular large B-cell lymphoma (IVLBCL) is a rare and aggressive type of B-cell lymphoma with large cells growing within the lumen of blood vessels. Although previous reports revealed highly variable symptoms resulting from small-vessel occlusion by neoplastic cells in a variety of organs, there are few reports of IVLBCL with pituitary involvement.

methodWe present a case of IVLBCL with pituitary infiltration from our institution together with a literature review of similar cases to better understand this rare case of IVLBCL involving the pituitary gland.

resultsOur case and the pertinent literature demonstrated that IVLBCL with pituitary involvement predominantly occurred in women at a mean age of 64 years, and most of them showed panhypopituitarism that was reversible after standard therapy of rituximab-containing chemotherapy with intrathecal methotrexate. Notably, the pituitary biopsy in our case revealed that atypical large B-cells found within blood vessels and the pituitary gland were negative for intercellular adhesion molecule 1. Intercellular adhesion molecule 1-negative lymphoid cells may have contributed to panhypopituitarism by extravasation into the pituitary tissues, which do not have a blood-brain barrier and receive abundant blood flow.

conclusionIVLBCL of the pituitary gland is a rare lymphoma with nonspecific manifestations and a dismal prognosis. Recognition of the clinicopathological features is necessary for early clinical diagnosis and appropriate treatment.

Indexed as

ACTH, adrenocorticotropic hormoneBAL, bronchoalveolar lavage fluid analysisCRH, corticotropin-releasing hormoneFDG, 18F-fluorodeoxyglucoseFSH, follicle-stimulating hormoneGH, growth hormoneGHRP2, growth hormone-releasing peptide 2hypopituitarismICAM1ICAM1, intercellular adhesion molecule 1intravascularIVLBCL, intravascular large B-cell lymphomalarge B-cell lymphomaLDH, lactate dehydrogenaseLH, luteinizing hormoneLHRH, luteinizing hormone-releasing hormoneMEAM, ranimustine, etoposide, cytarabine, and melphalanMTX, methotrexatepituitaryR-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisoloneR-hyper-CVAD/MA, rituximab plus hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and cytarabinesIL2R, soluble IL-2 receptorTBLB, transbronchial lung biopsyTRH, thyrotropin-releasing hormoneTSH, thyrotropin

Identifiers

PMID34307847
PMCPMC8282537
OpenAlexW3128613778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.